|
[1]
|
Ng, S.C., Shi, H.Y., Hamidi, N., et al. (2017) Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21st Century: A Systematic Review of Population-Based Studies. The Lancet, 390, 2769-2778. [Google Scholar] [CrossRef]
|
|
[2]
|
Kaplan, G.G. (2015) The Global Burden of IBD: from 2015 to 2025. Nature Reviews Gastroenterology & Hepatology, 12, 720-727. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Guan, Q. (2019) A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. Journal of Immunology Research, 2019, Article ID: 7247238. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Gonczi, L., Bessissow, T. and Lakatos, P.L. (2019) Disease Monitoring Strategies in Inflammatory Bowel Diseases: What Do We Mean by “tight Control”? World Journal of Gastroenterology, 25, 6172-6189. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
吴开春, 梁洁, 冉志华, 等. 炎症性肠病诊断与治疗的共识意见(2018年∙北京) [J]. 中国实用内科杂志, 2018, 38(9): 796-813.
|
|
[6]
|
Ahmadi, A.A. and Polyak, S. (2007) Endoscopy/Surveillance in Inflammatory Bowel Disease. The Surgical Clinics of North America, 87, 743-762. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Schmidt, A., Fuchs, K.H., Caca, K., et al. (2016) The Endoscopic Treatment of Iatrogenic Gastrointestinal Perforation. Deutsches Arzteblatt International, 113, 121-128. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Buisson, A., Gonzalez, F., Poullenot, F., et al. (2017) Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 23, 1425-1433. [Google Scholar] [CrossRef]
|
|
[9]
|
Califf, R.M. (2018) Biomarker Definitions and Their Applications. Experimental Biology and Medicine, 243, 213-221. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Marnell, L., Mold, C. and Du Clos, T.W. (2005) C-Reactive Protein: Ligands, Receptors and Role in Inflammation. Clinical Immunology, 117, 104-111. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Gewurz, H., Mold, C., Siegel, J., et al. (1982) C-Reactive Protein and the Acute Phase Response. Advances in Internal Medicine, 27, 345-372.
|
|
[12]
|
Turner, D., Mack, D.R., Hyams, J., et al. (2011) C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR) or Both? A Systematic Evaluation in Pediatric Ulcerative Colitis. Journal of Crohn’s & Colitis, 5, 423-429. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Khanna, R., Nelson, S.A., Feagan, B.G., et al. (2016) Endoscopic Scoring Indices for Evaluation of Disease Activity in Crohn’s Disease. The Cochrane Database of Systematic Reviews, 8, CD010642. [Google Scholar] [CrossRef]
|
|
[14]
|
Yoon, J.Y., Park, S.J., Hong, S.P., et al. (2014) Correlations of C-Reactive Protein Levels and Erythrocyte Sedimentation Rates with Endoscopic Activity Indices in Patients with Ulcerative Colitis. Digestive Diseases and Sciences, 59, 829-837. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Henriksen, M., Jahnsen, J., Lygren, I., et al. (2008) C-Reactive Protein: A Predictive Factor and Marker of Inflammation in Inflammatory Bowel Disease. Results from a Prospective Population-Based Study. Gut, 57, 1518-1523. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Jürgens, M., Mahachie, John, J.M., Cleynen, I., et al. (2011) Levels of C-Reactive Protein Are Associated with Response to Infliximab Therapy in Patients with Crohn’s Disease. Clinical Gastroenterology and Hepatology, 9, 421-427.E1. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Karakas, M. and Koenig, W. (2009) CRP in Cardiovascular Disease. Herz, 34, 607-613. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Pope, J.E. and Choy, E.H. (2021) C-Reactive Protein and Implications in Rheumatoid Arthritis and Associated Comorbidities. Seminars in Arthritis and Rheumatism, 51, 219-229. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Solem, C.A., Loftus, E.V., Tremaine, W.J., et al. (2005) Correlation of C-Reactive Protein with Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 11, 707-712. [Google Scholar] [CrossRef]
|
|
[20]
|
Alper, A., Zhang, L. and Pashankar, D.S. (2017) Correlation of Erythrocyte Sedimentation Rate and C-Reactive Protein with Pediatric Inflammatory Bowel Disease Activity. Journal of Pediatric Gastroenterology and Nutrition, 65, e25-e27. [Google Scholar] [CrossRef]
|
|
[21]
|
Kyle, B.D., Agbor, T.A., Sharif, S., et al. (2021) Fecal Calprotectin, CRP and Leucocytes in IBD Patients: Comparison of Biomarkers with Biopsy Results. Journal of the Canadian Association of Gastroenterology, 4, 84-90. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Henderson, P., Kennedy, N.A., Van Limbergen, J.E., et al. (2015) Serum C-Reactive Protein and CRP Genotype in Pediatric Inflammatory Bowel Disease: Influence on Phenotype, Natural History, and Response to Therapy. Inflammatory Bowel Diseases, 21, 596-605. [Google Scholar] [CrossRef]
|
|
[23]
|
Kucharz, E. (1987) Edmund Biernacki and the Erythrocyte Sedimentation Rate. Lancet, 1, 696. [Google Scholar] [CrossRef]
|
|
[24]
|
Grzybowski, A. and Sak, J. (2011) Who Discovered the Erythrocyte Sedimentation Rate? The Journal of Rheumatology, 38, 1521-1522. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Bray, C., Bell, L.N., Liang, H., et al. (2016) Erythrocyte Sedimentation Rate and C-Reactive Protein Measurements and Their Relevance in Clinical Medicine. WMJ: Official Publication of the State Medical Society of Wisconsin, 115, 317-321.
|
|
[26]
|
Alende-Castro, V., Alonso-Sampedro, M., Vazquez-Temprano, N., et al. (2019) Factors Influencing Erythrocyte Sedimentation Rate in Adults: New Evidence for an Old Test. Medicine, 98, e16816. [Google Scholar] [CrossRef]
|
|
[27]
|
Keenan, R.T., Swearingen, C.J. and Yazici, Y. (2008) Erythrocyte Sedimentation Rate and C-Reactive Protein Levels Are Poorly Correlated with Clinical Measures of Disease Activity in Rheumatoid Arthritis, Systemic Lupus Erythematosus and Osteoarthritis Patients. Clinical and Experimental Rheumatology, 26, 814-819.
|
|
[28]
|
Yayan, J. (2012) Erythrocyte Sedimentation Rate as a Marker for Coronary Heart Disease. Vascular Health and Risk Management, 8, 219-223. [Google Scholar] [CrossRef]
|
|
[29]
|
张慧. 炎症性肠病血清RDW、ESR、ESR/CRP与疾病严重程度及疾病活动程度的关系[J]. 中国肛肠病杂志, 2023, 43(1): 36-38.
|
|
[30]
|
Li, T., Qian, Y., Bai, T., et al. (2022) Prediction of Complications in Inflammatory Bowel Disease Using Routine Blood Parameters at Diagnosis. Annals of Translational Medicine, 10, Article 185. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Colombet, I., Pouchot, J., Kronz, V., et al. (2010) Agreement between Erythrocyte Sedimentation Rate and C-Reactive Protein in Hospital Practice. The American Journal of Medicine, 123, 863.E7-863.E13. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Zimmer, D.B., Eubanks, J.O., Ramakrishnan, D. and Criscitiello, M.F. (2013) Evolution of the S100 Family of Calcium Sensor Proteins. Cell Calcium, 53, 170-179.
https://pubmed.ncbi.nlm.nih.gov/23246155/
|
|
[33]
|
Andersson, K.B., Sletten, K., Berntzen, H.B., et al. (1988) The Leucocyte L1 Protein: Identity with the Cystic Fibrosis Antigen and the Calcium-Binding MRP-8 and MRP-14 Macrophage Components. Scandinavian Journal of Immunology, 28, 241-245. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Menees, S.B., Powell, C., Kurlander, J., et al. (2015) A Meta-Analysis of the Utility of C-Reactive Protein, Erythrocyte Sedimentation Rate, Fecal Calprotectin, and Fecal Lactoferrin to Exclude Inflammatory Bowel Disease in Adults with IBS. The American Journal of Gastroenterology, 110, 444-454. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Lee, Y.J. and Park, J.H. (2022) Fecal Calprotectin Assay at an Early Stage of Treatment Can Be Used as a Surrogate Marker to Predict Clinical Remission and Mucosal Healing in Pediatric Crohn’s Disease. Pediatric Gastroenterology, Hepatology & Nutrition, 25, 396-405. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Sipponen, T., Savilahti, E., Kolho, K.L., et al. (2008) Crohn’s Disease Activity Assessed by Fecal Calprotectin and Lactoferrin: Correlation with Crohn’s Disease Activity Index and Endoscopic Findings. Inflammatory Bowel Diseases, 14, 40-46. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Roblin, X., Duru, G., Williet, N., et al. (2017) Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn’s Disease. Inflammatory Bowel Diseases, 23, 126-132. [Google Scholar] [CrossRef]
|
|
[38]
|
Baveye, S., Elass, E., Mazurier, J., et al. (1999) Lactoferrin: A Multifunctional Glycoprotein Involved in the Modulation of the Inflammatory Process. Clinical Chemistry and Laboratory Medicine, 37, 281-286. [Google Scholar] [CrossRef]
|
|
[39]
|
Wang, B., Timilsena, Y.P., Blanch, E. and Adhikari, B. (2019) Lactoferrin: Structure, Function, Denaturation and Digestion. Critical Reviews in Food Science and Nutrition, 59, 580-596.
|
|
[40]
|
Connell, S., Kawashima, M., Nakamura, S., et al. (2021) Lactoferrin Ameliorates Dry Eye Disease Potentially through Enhancement of Short-Chain Fatty Acid Production by Gut Microbiota in Mice. International Journal of Molecular Sciences, 22, Article 12384. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Dai, J., Liu, W.Z., Zhao, Y.P., et al. (2007) Relationship between Fecal Lactoferrin and Inflammatory Bowel Disease. Scandinavian Journal of Gastroenterology, 42, 1440-1444. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Mohamed, W.A., Salama, R.M. and Schaalan, M.F. (2019) A Pilot Study on the Effect of Lactoferrin on Alzheimer’s Disease Pathological Sequelae: Impact of the P-Akt/PTEN Pathway. Biomedicine & Pharmacotherapy, 111, 714-723. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Kane, S.V., Sandborn, W.J., Rufo, P.A., et al. (2003) Fecal Lactoferrin Is a Sensitive and Specific Marker in Identifying Intestinal Inflammation. The American Journal of Gastroenterology, 98, 1309-1314. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Łykowska-Szuber, L., Klimczak, K., Eder, P., et al. (2016) Diagnostic Importance of Faecal Markers in Long-Term Monitoring of Anti-TNF-α Therapy in Primary Responders with Crohn’s Disease. Przeglad Gastroenterologiczny, 11, 232-238. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Rubio, M.G., Amo-Mensah, K., Gray, J.M., et al. (2019) Fecal Lactoferrin Accurately Reflects Mucosal Inflammation in Inflammatory Bowel Disease. World Journal of Gastrointestinal Pathophysiology, 10, 54-63. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Gisbert, J.P., Bermejo, F., Pérez-Calle, J.L., et al. (2009) Fecal Calprotectin and Lactoferrin for the Prediction of Inflammatory Bowel Disease Relapse. Inflammatory Bowel Diseases, 15, 1190-1198. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Scarpa, M., D’Incà, R., Basso, D., et al. (2007) Fecal Lactoferrin and Calprotectin after Ileocolonic Resection for Crohn’s Disease. Diseases of the Colon and Rectum, 50, 861-869. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Lasson, A., Stotzer, P.O., Öhman, L., et al. (2015) The Intra-Individual Variability of Faecal Calprotectin: A Prospective Study in Patients with Active Ulcerative Colitis. Journal of Crohn’s & Colitis, 9, 26-32. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Cherfane, C.E., Gessel, L., Cirillo, D., et al. (2015) Monocytosis and a Low Lymphocyte to Monocyte Ratio Are Effective Biomarkers of Ulcerative Colitis Disease Activity. Inflammatory Bowel Diseases, 21, 1769-1775. [Google Scholar] [CrossRef]
|
|
[50]
|
Chen, Y.H., Wang, L., Feng, S.Y., et al. (2020) The Relationship between C-Reactive Protein/Albumin Ratio and Disease Activity in Patients with Inflammatory Bowel Disease. Gastroenterology Research and Practice, 2020, Article ID: 3467419. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Jeong, Y., Jeon, S.R., Kim, H.G., et al. (2021) The Role of Platelet to Lymphocyte Ratio and Neutrophil to Lymphocyte Ratio in Ulcerative Colitis. Intestinal Research, 19, 62-70. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Gao, S.Q., Huang, L.D., Dai, R.J., et al. (2015) Neutrophil-Lymphocyte Ratio: A Controversial Marker in Predicting Crohn’s Disease Severity. International Journal of Clinical and Experimental Pathology, 8, 14779-14785.
|
|
[53]
|
Glapa-Nowak, A., Szczepanik, M., Banaszkiewicz, A., et al. (2022) C-Reactive Protein/Albumin Ratio at Diagnosis of Pediatric Inflammatory Bowel Disease: A Retrospective Multi-Center Study. Medical Science Monitor, 28, e937842. [Google Scholar] [CrossRef]
|
|
[54]
|
Metwally, R.H. (2022) Can Neutrophil/Lymphocyte Ratio Assess Inflammatory Bowel Disease Activity and Severity in Children? The Turkish Journal of Gastroenterology, 33, 1058-1061. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Feng, W., Liu, Y., Zhu, L., et al. (2022) Evaluation of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Potential Markers for Ulcerative Colitis: A Retrospective Study. BMC Gastroenterology, 22, Article No. 485. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Zhou, F.S., Gao, N., Sun, X., et al. (2021) C-Reactive Protein/Abumin Ratio Is a Useful Biomarker for Predicting the Mucosal Healing in the Crohn Disease: A Retrospective Study. Medicine, 100, e24925. [Google Scholar] [CrossRef]
|
|
[57]
|
Feng, W., Zhu, L., Liu, Y., et al. (2023) C-Reactive Protein/Albumin Ratio and IL-6 Are Associated with Disease Activity in Patients with Ulcerative Colitis. Journal of Clinical Laboratory Analysis, 37, e24843. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Pan, J., Li, J. and Gao, Y. (2023) The Value of 7 Peripheral Blood Serum Ratios in Diagnosis and Prediction of Disease Activity of Patients within Inflammatory Bowel Disease Individuals. Frontiers in Medicine, 10, Article 1122005. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Wang, Y., Li, C., Wang, W., et al. (2022) Serum Albumin to Globulin Ratio Is Associated with the Presence and Severity of Inflammatory Bowel Disease. Journal of Inflammation Research, 15, 1907-1920. [Google Scholar] [CrossRef]
|
|
[60]
|
Yagi, S., Furukawa, S., Shiraishi, K., et al. (2023) The Albumin to Globulin Ratio Is Associated with Clinical Outcome in Japanese Patients with Ulcerative Colitis. Annals of Coloproctology, 39, 155-163. [Google Scholar] [CrossRef] [PubMed]
|
|
[61]
|
Anderson, A., Cherfane, C., Click, B., et al. (2022) Monocytosis Is a Biomarker of Severity in Inflammatory Bowel Disease: Analysis of a 6-Year Prospective Natural History Registry. Inflammatory Bowel Diseases, 28, 70-78. [Google Scholar] [CrossRef] [PubMed]
|
|
[62]
|
Ishida, N., Asai, Y., Miyazu, T., et al. (2022) Lymphocyte-to-Monocyte Ratio Is a Short-Term Predictive Marker of Ulcerative Colitis after Induction of Advanced Therapy. Gastroenterology Report, 10, goac025. [Google Scholar] [CrossRef] [PubMed]
|
|
[63]
|
Takahashi, N., Takahashi, Y. and Putnam, F.W. (1985) Periodicity of Leucine and Tandem Repetition of a 24-Amino Acid Segment in the Primary Structure of Leucine-Rich α 2-Glycoprotein of Human Serum. Proceedings of the National Academy of Sciences of the United States of America, 82, 1906-1910. [Google Scholar] [CrossRef] [PubMed]
|
|
[64]
|
Yasutomi, E., Inokuchi, T., Hiraoka, S., et al. (2021) Leucine-Rich α-2 Glycoprotein as a Marker of Mucosal Healing in Inflammatory Bowel Disease. Scientific Reports, 11, Article No. 11086. [Google Scholar] [CrossRef] [PubMed]
|
|
[65]
|
Shinzaki, S., Matsuoka, K., Iijima, H., et al. (2017) Leucine-Rich α-2 Glycoprotein Is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. Journal of Crohn’s & Colitis, 11, 84-91. [Google Scholar] [CrossRef] [PubMed]
|
|
[66]
|
Shimoyama, T., Yamamoto, T., Yoshiyama, S., et al. (2023) Leucine-Rich α-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 29, 1399-1408. [Google Scholar] [CrossRef] [PubMed]
|
|
[67]
|
Yasuda, R., Arai, K., Kudo, T., et al. (2023) Serum Leucine-Rich α-2 Glycoprotein and Calprotectin in Children with Inflammatory Bowel Disease: A Multicenter Study in Japan. Journal of Gastroenterology and Hepatology, 38, 1131-1139. [Google Scholar] [CrossRef] [PubMed]
|
|
[68]
|
Yoshida, T., Shimodaira, Y., Fukuda, S., et al. (2022) Leucine-Rich α-2 Glycoprotein in Monitoring Disease Activity and Intestinal Stenosis in Inflammatory Bowel Disease. The Tohoku Journal of Experimental Medicine, 257, 301-308. [Google Scholar] [CrossRef]
|
|
[69]
|
Fukuhara, A., Matsuda, M., Nishizawa, M., et al. (2005) Visfatin: A Protein Secreted by Visceral Fat That Mimics the Effects of Insulin. Science, 307, 426-430. [Google Scholar] [CrossRef] [PubMed]
|
|
[70]
|
Dakroub, A., A.Nasser, S., Younis, N., et al. (2020) Visfatin: A Possible Role in Cardiovasculo-Metabolic Disorders. Cells, 9, Article 2444. [Google Scholar] [CrossRef] [PubMed]
|
|
[71]
|
Saadoun, M.M., Nosair, N.A., Abdel-Azeez, H.A.H., et al. (2021) Serum Visfatin as a Diagnostic Marker of Active Inflammatory Bowel Disease. Journal of Gastrointestinal and Liver Diseases, 30, 339-345. [Google Scholar] [CrossRef] [PubMed]
|
|
[72]
|
Neubauer, K., Bednarz-Misa, I., Walecka-Zacharska, E., et al. (2019) Oversecretion and Overexpression of Nicotinamide Phosphoribosyltransferase/Pre-B Colony-Enhancing Factor/Visfatin in Inflammatory Bowel Disease Reflects the Disease Activity, Severity of Inflammatory Response and Hypoxia. International Journal of Molecular Sciences, 20, Article 166. [Google Scholar] [CrossRef] [PubMed]
|
|
[73]
|
Sindrewicz, P., Lian, L.Y. and Yu, L.G. (2016) Interaction of the Oncofetal Thomsen-Friedenreich Antigen with Galectins in Cancer Progression and Metastasis. Frontiers in Oncology, 6, Article 79. [Google Scholar] [CrossRef] [PubMed]
|
|
[74]
|
Yu, T.B., Dodd, S., Yu, L.G. and Subramanian, S. (2020) Serum Galectins as Potential Biomarkers of Inflammatory Bowel Diseases. PLOS ONE, 15, e0227306. [Google Scholar] [CrossRef] [PubMed]
|
|
[75]
|
Kessel, C., Lavric, M., Weinhage, T., et al. (2021) Serum Biomarkers Confirming Stable Remission in Inflammatory Bowel Disease. Scientific Reports, 11, Article No. 6690. [Google Scholar] [CrossRef] [PubMed]
|
|
[76]
|
Papa-Gobbi, R., Muglia, C.I., Rocca, A., et al. (2021) Spatiotemporal Regulation of Galectin-1-Induced T-Cell Death in Lamina Propria from Crohn’s Disease and Ulcerative Colitis Patients. Apoptosis, 26, 323-337. [Google Scholar] [CrossRef] [PubMed]
|
|
[77]
|
Cibor, D., Szczeklik, K., Brzozowski, B., Mach, T. and Owczarek, D. (2019) Serum Galectin 3, Galectin 9 and Galectin 3-Binding Proteins in Patients with Active and Inactive Inflammatory Bowel Disease. Journal of Physiology and Pharmacology, 70.
|
|
[78]
|
Wishart, D.S. (2019) Metabolomics for Investigating Physiological and Pathophysiological Processes. Physiological Reviews, 99, 1819-1875. [Google Scholar] [CrossRef] [PubMed]
|
|
[79]
|
Ma, R., Zhu, Y., Li, X., et al. (2023) A Novel Serum Metabolomic Panel for the Diagnosis of Crohn’s Disease. Inflammatory Bowel Diseases, 29, 1524-1535. [Google Scholar] [CrossRef] [PubMed]
|
|
[80]
|
Schicho, R., Shaykhutdinov, R., Ngo, J., et al. (2012) Quantitative Metabolomic Profiling of Serum, Plasma, and Urine by 1H NMR Spectroscopy Discriminates between Patients with Inflammatory Bowel Disease and Healthy Individuals. Journal of Proteome Research, 11, 3344-3357. [Google Scholar] [CrossRef] [PubMed]
|
|
[81]
|
Scoville, E.A., Allaman, M.M., Brown, C.T., et al. (2018) Alterations in Lipid, Amino Acid, and Energy Metabolism Distinguish Crohn’s Disease from Ulcerative Colitis and Control Subjects by Serum Metabolomic Profiling. Metabolomics, 14, Article No. 17. [Google Scholar] [CrossRef] [PubMed]
|
|
[82]
|
Stephens, N.S., Siffledeen, J., Su, X., et al. (2013) Urinary NMR Metabolomic Profiles Discriminate Inflammatory Bowel Disease from Healthy. Journal of Crohn’s & Colitis, 7, e42-e48. [Google Scholar] [CrossRef] [PubMed]
|
|
[83]
|
Daniluk, U., Daniluk, J., Kucharski, R., et al. (2019) Untargeted Metabolomics and Inflammatory Markers Profiling in Children with Crohn’s Disease and Ulcerative Colitis—A Preliminary Study. Inflammatory Bowel Diseases, 25, 1120-1128. [Google Scholar] [CrossRef] [PubMed]
|
|
[84]
|
Parada Venegas, D., De La Fuente, M.K., Landskron, G., et al. (2019) Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Frontiers in Immunology, 10, Article 277. [Google Scholar] [CrossRef] [PubMed]
|
|
[85]
|
Taylor, H., Serrano-Contreras, J.I., McDonald, J.A.K., et al. (2020) Multiomic Features Associated with Mucosal Healing and Inflammation in Paediatric Crohn’s Disease. Alimentary Pharmacology & Therapeutics, 52, 1491-1502. [Google Scholar] [CrossRef] [PubMed]
|
|
[86]
|
Kolho, K.L., Pessia, A., Jaakkola, T., et al. (2017) Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. Journal of Crohn’s & Colitis, 11, 321-334. [Google Scholar] [CrossRef] [PubMed]
|
|
[87]
|
Shkoda, A., Werner, T., Daniel, H., et al. (2007) Differential Protein Expression Profile in the Intestinal Epithelium from Patients with Inflammatory Bowel Disease. Journal of Proteome Research, 6, 1114-1125. [Google Scholar] [CrossRef] [PubMed]
|
|
[88]
|
Zhao, Y., Liu, X., Qu, Y., et al. (2019) The Roles of P38 MAPK → COX2 and NF-κB → COX2 Signal Pathways in Age-Related Testosterone Reduction. Scientific Reports, 9, Article No. 10556. [Google Scholar] [CrossRef] [PubMed]
|
|
[89]
|
Yau, Y.Y., Leong, R.W.L., Pudipeddi, A., et al. (2017) Serological Epithelial Component Proteins Identify Intestinal Complications in Crohn’s Disease. Molecular & Cellular Proteomics, 16, 1244-1257. [Google Scholar] [CrossRef]
|
|
[90]
|
Starr, A.E., Deeke, S.A., Ning, Z., et al. (2017) Proteomic Analysis of Ascending Colon Biopsies from a Paediatric Inflammatory Bowel Disease Inception Cohort Identifies Protein Biomarkers That Differentiate Crohn’s Disease from UC. Gut, 66, 1573-1583. [Google Scholar] [CrossRef] [PubMed]
|
|
[91]
|
Seeley, E.H., Washington, M.K., Caprioli, R.M., et al. (2013) Proteomic Patterns of Colonic Mucosal Tissues Delineate Crohn’s Colitis and Ulcerative Colitis. Proteomics. Clinical Applications, 7, 541-549. [Google Scholar] [CrossRef] [PubMed]
|
|
[92]
|
Kanmura, S., Uto, H., Numata, M., et al. (2009) Human Neutrophil Peptides 1-3 Are Useful Biomarkers in Patients with Active Ulcerative Colitis. Inflammatory Bowel Diseases, 15, 909-917. [Google Scholar] [CrossRef] [PubMed]
|
|
[93]
|
Heier, C.R., Fiorillo, A.A., Chaisson, E., et al. (2016) Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease. Clinical and Translational Gastroenterology, 7, e192. [Google Scholar] [CrossRef] [PubMed]
|